Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts.

Armstrong, D.K.B.; Maw, R D; Dinsmore, W W; Blaakær, Jan; Corrêa, Marcos Antônio; Falk, L.; Ferenczy, Alex; Fortier, Michel; Frazer, Ian H.; Law, Carmella; Moller, Bridget; Oyakawa, N.

doi:10.1136/sti.72.2.103

Cited by 12 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recurrence rate in the IFNtreated patient group was significantly lower compared to that seen in the group receiving placebo. No significant difference in tolerance, however, was noted between cycli cally administered rIFN-a?a at low dose (l million IU per day injection) and placebo [57], The results obtained in this study with the cyclic rIFN-a?a treatment regimen was more effective than results observed in previous studies where a continuous IFN-a?a treatment was used [51,52,55,56,58,59].…”

Section: Adjuvant Interferon Therapycontrasting

confidence: 56%

Therapy of Human Papillomavirus Infection and Associated Epithelial Tumors

Gross

1997

Intervirology

View full text Add to dashboard Cite

Papillomavirus infections are very common and cause various benign and malignant lesions, most notably condyloma acuminatum, anogenital cancer, laryngeal papilloma and skin warts. Unfortunately, effective therapy is currently not available. Therapeutic options are limited, expensive and often ineffective. They comprise cytodestructive and cytotoxic substances, surgical methods, laser and cryotherapy. Immunotherapy seems to be one of the more promising options. Interferons combined with ablative methods such as CO2 laser can prevent recurrence of disease. Cytokine enhancement is an old concept that has shown effectiveness with imidazoquinolinamine derivatives (imiquimod). Imiquimod was released recently for therapy of genital warts. Currently, HPV vaccines are being developed to protect against infection with HPV and to treat existing warts and other HPV-associated lesions. Some processes in the HPV infection cycle have been determined as possible targets for the development of specific antiviral agents. Cidofovir is a primordial antiviral substance active against HPV. Unfortunately, there is a potential risk for side effects.

show abstract

Section: Adjuvant Interferon Therapycontrasting

confidence: 56%

Therapy of Human Papillomavirus Infection and Associated Epithelial Tumors

Gross

1997

Intervirology

View full text Add to dashboard Cite

show abstract

“…1 In the absence of specific anti-HPV agents, conventional management for genital warts is often associated with unsatisfactory response rates and high recurrence rates. 2 Since most applicable methods act locally, the use of a systemic agent may more effectively control the virus.…”

mentioning

confidence: 99%

Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: a randomised placebo controlled trial

Georgala

Katoulis²,

Georgala³

et al. 2004

Sexually Transmitted Infections

View full text Add to dashboard Cite

Background: Conventional therapies for human papillomavirus (HPV) infection are often associated with unsatisfactory response rates and high recurrence rates. The use of a systemic agent may more effectively control the virus. Objectives: To investigate the efficacy and safety of low dose oral isotretinoin in recalcitrant condylomata acuminata (RCA) of the cervix. Methods: Double blind placebo controlled clinical trial. 60 women, aged 21-43 years, with RCA of the cervix, refractory to at least one conventional therapy, were randomly assigned to receive either isotretinoin, 0.5 mg/kg daily for 12 weeks (group 1), or placebo (group 2). Results: Of the 28 evaluable group 1 patients, nine (32.1%) responded to the treatment completely, 11 (39.2%) responded partially, and eight (28.5%) did not respond. Of the 25 group 2 patients, no one responded to the treatment completely, two (8%) responded partially, and 23 (92%) did not respond. The therapeutic difference between patients receiving active and placebo therapy was statistically significant (x 2 = 19.35, p,0.001). Only one (11.1%) of the complete responders experienced recurrence during the 12 month follow up. Side effects were generally mild and resolved upon completion of therapy. Conclusions: Compared to placebo, low dose oral isotretinoin showed considerable efficacy with insignificant and reversible side effects and a low recurrence rate. Isotretinoin may represent an efficacious and safe alternative systemic form of therapy for RCA of the cervix.

show abstract

“…Response was evaluated by recording the number of lesions and by bi‐dimensional measurements of the lesions, mapped on a schematic diagram of the cervix. The bi‐dimensional measurements were expressed as a single parameter, which was the affected area in millimetres 2 . This study was performed at entry, every 4 weeks thereafter and at the end of therapy.…”

Section: Methodsmentioning

confidence: 99%

“…In the absence of specific anti‐HPV agents, various therapeutic approaches have been tried, including chemotherapeutic or immunomodulatory agents and cytodestructive methods. Conventional management is seldom devoid of adverse effects, and it is often associated with unsatisfactory response rates and high recurrence rates 2 . Most of these methods aim to remove clinically apparent lesions, while latent HPV infection may remain.…”

Section: Introductionmentioning

confidence: 99%

Short communication: Oral inosiplex in the treatment of cervical condylomata acuminata: a randomised placebo‐controlled trial

Georgala¹,

Katoulis²,

Befon³

et al. 2006

BJOG

View full text Add to dashboard Cite

Conventional therapies for human papillomavirus infection aim to remove clinically apparent lesions, while latent infection may remain, representing a threat for transmission and carcinogenesis. The use of a systemic agent may more effectively control the virus. We conducted a randomised placebo‐controlled study to investigate the efficacy and safety of oral inociplex in the treatment of cervical condylomata acuminata (CA) that had been resistant to conventional therapies. Thirty‐eight white European women, aged 20–43 years, with genital warts of the cervix, refractory to at least one conventional therapy, were randomly assigned to receive either inosiplex, 50 mg/kg daily peros for 12 weeks (group 1), or placebo (group 2). Of the 17 evaluable group 1 women, 4 responded to the treatment completely, 7 responded partially and 6 did not respond. Of the 19 group 2 women, none responded to the treatment completely, 3 responded partially and 16 did not respond. The therapeutic difference between women receiving active and placebo therapy was statistically significant (χ2= 6.69, P < 0.01) and remained significant when an intention‐to‐treat analysis was performed (χ2= 7.69, P < 0.01). None of the complete responders experienced recurrence during the 12‐month follow up. Adverse effects were mild and resolved upon completion of therapy. Compared with placebo, inosiplex showed considerable efficacy with insignificant and reversible adverse effects and without recurrences. Inosiplex may represent an efficacious and safe alternative systemic form of therapy for cervical genital warts.

show abstract

Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts.

Cited by 12 publications

References 16 publications

Therapy of Human Papillomavirus Infection and Associated Epithelial Tumors

Therapy of Human Papillomavirus Infection and Associated Epithelial Tumors

Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: a randomised placebo controlled trial

Short communication: Oral inosiplex in the treatment of cervical condylomata acuminata: a randomised placebo‐controlled trial

Contact Info

Product

Resources

About